January 22, 2018 / 7:03 PM / 3 months ago

BRIEF-Nymox Reports 5-Yr Results From Prostate Cancer Study Of Fexapotide Triflutate In 146 U.S. Men

Jan 22 (Reuters) - Nymox Pharmaceutical Corp:

* NYMOX REPORTS 5-YEAR RESULTS FROM PROSPECTIVE RANDOMIZED CONTROLLED PROSTATE CANCER STUDY OF FEXAPOTIDE TRIFLUTATE IN 146 U.S. MEN

* NYMOX - HIGH DOSE FEXAPOTIDE 15MG SINGLE DOSAGE TREATMENT RESULTED IN 80% LESS SURGERY OR RADIOTHERAPY ASSOCIATED WITH GLEASON GRADE PROGRESSION

* NYMOX PHARMACEUTICAL CORP - STUDY ALSO SHOWED THAT BOTH DOSES OF FEXAPOTIDE WERE CONSISTENTLY EFFECTIVE Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below